RxDoctor Payments Data

Steven Unterman, MD

Ophthalmology · Prairie Village, KSNPI 1447284880

Payments from drug & device makers

$548in general payments, 2019–2025

Across 16 payments — averaging $34.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$319
  • Optos, Inc.$54
  • The Cameron-ehlen Group, Inc.$34
  • Novartis$31
  • Harrow Eye, LLC$24
  • Kala Pharmaceuticals, Inc.$22
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$548 in reported general payments places this provider in the 25th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$288,845
Medicare patients
619
Services billed
2,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine82$75,627
LumiganBimatoprost129$50,045
SimbrinzaBrinzolamide/Brimonidine Tart39$10,712
Travoprost58$10,489
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol51$8,576
Prednisolone Acetate201$6,815
Cyclosporine12$5,769
RocklatanNetarsudil Mesylat/Latanoprost16$5,412
RhopressaNetarsudil Mesylate14$4,517
Latanoprost314$3,703
MoxifloxacinMoxifloxacin Hcl95$2,369
Loteprednol Etabonate13$2,353
Timolol Maleate148$1,964
Fluorometholone33$1,887
Brinzolamide12$1,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$12$125,672211 claims
AlconSimbrinza$319$10,71239 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$17$9,92930 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$17$2,35313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Prairie Village

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →